Pancreatic islet cell carcinoma: Difference between revisions
Jump to navigation
Jump to search
| Line 210: | Line 210: | ||
* [[Numbness]] caused due to [[hypokalaemia]] | * [[Numbness]] caused due to [[hypokalaemia]] | ||
* [[Flushing|Flushin]]<nowiki/>g | * [[Flushing|Flushin]]<nowiki/>g | ||
=== Physical examination === | |||
* | |||
* | * | ||
Revision as of 21:54, 5 November 2018
| Pancreatic islet cell carcinoma |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cancer of the endocrine pancreas includes a highly treatable and often curable collection of tumors.
Classification
Pancreatic islet cell carcinoma is of 6 types:
- Glucagonoma
- Non functional islet cell tumor
Pathophysiology
- Acinar cells and Islet cells are the 2 types of cells in pancreas.
- Acinar cells are responsible for secretion of enzymes and bicarbonate involved in the digestion process.
- Islet cells of pancreas play the endocrine organ role, by producing hormones such as insulin, gastrin, glucagon, somatostatin and vasocative intestinal polypeptide.
- The pancreatic islet cell carcinomas are also known as neuroendocrine tumors.
- They can occur sporadically or in association with other disorders such as multiple endocrine neoplasia type 1, Von Hippel Lindau disease, neurofibromatosis type 1 and tuberous sclerosis which are inherited in an autosomal dominant pattern.
- Islet cell carcinoma is divided into 6 types depending on the type of hormone produced.
- These tumors produce excessive amounts of hormones and cause symptoms similar to the hormones' action.
- Insulinoma - hypoglycemia due to decreased glucose synthesis in liver.
- Gastrinoma - Zollinger-Ellison syndrome, in which hypersecretion of gastrin causes hydrochloric acid release which causes peptic ulcers.
- Glucagonoma - hyperglucagonemia, zinc deficiency, fatty acid deficiency, hypoaminoacidemia that may cause necrolytic migratory erythema.
- VIPoma - Elevated serum VIP levels leads to increased intracellular cAMP which causes increased intestinal secretion of water along with Na+, K+, HCO3 -, and Cl- in the intestinal lumen, causing diarrhea and hypokalemia.
- Somatostatinoma - increased release of somatostatin causes gallstones, diarrhea and fat malabsorption resulting in steatorrhea.
- Non functional islet cell tumor- These do not produce any hormones, symptoms depend on the size and metastasis.
- The tumor cells are usually round with regular bland nuclei which produce large number of secretory granules with diffuse immunoexpression of neuroendocrinemarkers.
- The poorly differentiated neuroendocrine tumor (NET) shows an atypical, sheet-like, diffuse and irregular nuclei, less cytoplasmic secretory granules, and limited biomarker immunoexpression.
- Head of the pancreas is most commonly involved (75% of cases) followed by the tail.
- The most common metastatic sites are the liver, the lymph nodes, and the bones.
- Pancreatic islet cell carcinoma is divided into 3 grades by WHO.
2010 WHO grading system for pNETs
| Grade 1 (G1) | Grade 2 (G2) | Grade 3 (G3) | |
|---|---|---|---|
| Ki-67 index | <3% | 3-20% | >20% |
| Mitotic count | <2/10 HPF | 2-20/10 HPF | >20/10 HPF |
| Differentiation | Well differentiated | Well differentiated | Poorly differentiated |
| 5-year survival rate | 85% | 78% | 9% |
Causes
There are no established causes of pancreatic islet cell carcinoma but there is an association with MEN 1 syndrome and rarely with Von Hippel-Lindau disease, Neurofibromatosis-1 and Tuberous sclerosis.
Epidemiology and Demographics
- The incidence of pancreatic islet cell carcinoma is 1 in 100000 people.
Age
- It mostly occurs in fourth to sixth decades of life.
Gender
- Its incidence is equal in both males and females.
Race
- Race has no effect on the incidence.
Staging
Pancreatic cancer is staged according to the TNM staging system based on the primary tumor, lymph nodes involved and distant metastasis.
| TNM Classification for Pancreatic Cancer: | |
|---|---|
| Primary tumor | |
| TX | Primary tumor cannot be assessed |
| T0 | No evidence of primary tumor |
| Tis | Carcinoma in situ |
| T1 | Tumor limited to the pancreas, ≤2 cm in greatest dimension |
| T2 | Tumor limited to the pancreas, >2 cm in greatest dimension |
| T3 | Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery |
| T4 | Tumor involves the celiac axis or the superior mesenteric artery (unresectable primary tumor) |
| Regional lymph nodes | |
| NX | Regional lymph nodes cannot be assessed |
| N0 | No regional lymph node metastasis |
| N1 | Regional lymph node metastasis |
| Distant metastases | |
| MX | Distant metastasis cannot be assessed |
| M0 | No distant metastasis |
| M1 | Distant metastasis |
Screening
Screening for pancreatic islet cell carcinoma is not done.
Natural history, complications and prognosis
Natural history
- The cancer usually presents with jaundice, light-colored stools, dark urine, pain in the upper or middle abdomen and back, unexplained weight loss, anorexia, fatigue and symptoms according to the hormone produced.
- Patients with VIPoma may progress to develop watery diarrhea, abdominal pain, bloating, nausea, vomiting, skin rash, backache, flushing, and lethargy.
- The symptoms of insulinoma are found in any age group and start with neuroglycopenic symptoms such as altered mental status, visual disturbances, confusion and adrenergic symptoms such as profuse sweating, palpitations and tremors.
- Zollinger Ellison syndrome presents with refractory peptic ulcer disease, severe gastroesophageal reflux disease (GERD), diarrhea and finally death, mainly due to complications of the refractory peptic ulcer disease.
- Patients with glucagonoma may progress to develop necrolytic migratory erythema, cheilosis, stomatitis, diarrhea, polyuria, and polydipsia.
- Patients with somatostatinoma present with headaches, frequent urination, dry skin and mouth, or feeling hungry, thirsty, tired, or weak, diarrhea, steatorrhea and gallstones.
- If left untreated, patients may progress to develop exocrine pancreatic insufficiency arising from pancreatic duct obstruction leading to malabsorption, malnutrition and cachexia. Dudodenal obstruction and biliary obstruction may cause symptoms of bowel obstruction and jaundice.
- Metastasis may occur to different sites.
Complications
- Hematemesis
- Anemia
- Duodenal ulcer perforation
- Weight loss
- Seizures
- Coma
- Neuropsychiatric manifestations include depression, dementia, psychosis, and agitation
- Dilated cardiomyopathy
- Cardiac arrest from low blood potassium level
- Dehydration
- Obstructive jaundice can present with features of cholangitis:
- Duodenal obstruction
Prognosis
Prognosis of pancreatic islet cell carcinoma depends on the following:
- Whether or not the tumor can be removed by surgery.
- The stage of the tumor, the size of the tumor, whether cancer has spread outside the pancreas.
- The patient’s general health.
- Whether the tumor has just been diagnosed or has recurred.
- The presence of metastasis is associated with a particularly poor prognosis. Grade 1 and 2 tumor have the most favorable prognosis.
- The 10-year event free survival rate is less than 51.6% with metastasis and 64.3% without metastasis.
Diagnosis
Diagnostic findings
History and symptoms
- episodes of altered mental status/confusion
- Visual disturbances
- Sweating
- Negative history for exogenous insulin or oral hypoglycemic agents such as Sulfonylureas
- Palpitations
- Seizures
- Tremors
- Behavioral disturbances
- Weakness
- Abdominal pain
- Weight loss
- Loss of appetite
- Diarrhea
- Heart burn
- Necrolytic migratory erythema (NME) is a classical symptom observed in patients with glucagonoma and is present in 80% of cases. Associated NME is characterized by the spread of erythematous blisters and swelling across areas subject to greater friction and pressure, including the lower abdomen, buttocks, perineum, and groin.
- Polyuria
- Polydypsia
- Weight loss
- Numbness caused due to hypokalaemia
- Flushing
Physical examination
Treatment
Medical Therapy
Combination chemotherapy may provide effective palliation as well as increased survival in selected patients. In patients with indolent, slow-growing metastatic islet cell tumors, the best therapy may be careful observation and no treatment until palliation is required.
Surgery
Surgery is the only curative modality.[4,5] Even in those cases not resectable for cure, effective palliation may be achieved because of the slow-growing nature of the majority of these tumors and the potential use of antihormonal pharmacologic therapy (for example, cimetidine in the ulcer-producing Zollinger-Ellison syndrome).
Patients with multiple endocrine neoplasia syndrome type 1, an autosomal dominant condition in which 85% have pancreatic islet cell tumors, 90% have hyperparathyroidism, and 65% have pituitary tumors, are less likely to be cured by pancreatic resection than are patients with sporadic islet cell tumors. With the exception of pain relief from bone metastases, radiation therapy has a limited role in this disease[1].
References
- ↑ Modlin IM, Lewis JJ, Ahlman H, et al.: Management of unresectable malignant endocrine tumors of the pancreas. Surg Gynecol Obstet 176 (5): 507-18, 1993